1. Intravenous Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke: Phase1/2a Clinical Trial in a Homogeneous Group of Stroke Patients
- Author
-
Takashi Daimon, Nobuyuki Sakai, Kaori Doi, Chiaki Sakai, Akihiko Taguchi, Yukiko Kasahara, Nobuo Kohara, Masafumi Ihara, Kenichi Yamahara, Tomohiro Matsuyama, Toshihiro Soma, Kazuyuki Nagatsuka, Hiroaki Naritomi, Hiroyuki Nishimura, David M. Stern, and Katsufumi Kajimoto
- Subjects
Male ,medicine.medical_specialty ,Antigens, CD34 ,Bone Marrow Cells ,Biology ,Peripheral blood mononuclear cell ,Transplantation, Autologous ,Cell therapy ,Leukocyte Count ,Recurrence ,medicine ,Humans ,Clinical Trials ,Adverse effect ,Stroke ,Aged ,Bone Marrow Transplantation ,Cell Biology ,Hematology ,Middle Aged ,Autologous bone ,medicine.disease ,Surgery ,Transplantation ,Clinical trial ,Oxygen ,medicine.anatomical_structure ,Treatment Outcome ,Cerebrovascular Circulation ,Immunology ,Leukocytes, Mononuclear ,Cytokines ,Intercellular Signaling Peptides and Proteins ,Administration, Intravenous ,Female ,Bone marrow ,Developmental Biology - Abstract
The goal of this clinical trial was to assess the feasibility and safety of transplanting autologous bone marrow mononuclear cells into patients suffering severe embolic stroke. Major inclusion criteria included patients with cerebral embolism, age 20-75 years, National Institute of Health Stroke Scale (NIHSS) score displaying improvement of ≤ 5 points during the first 7 days after stroke, and NIHSS score of ≥ 10 on day 7 after stroke. Bone marrow aspiration (25 or 50 mL; N = 6 patients in each case) was performed 7-10 days poststroke, and bone marrow mononuclear cells were administrated intravenously. Mean total transplanted cell numbers were 2.5 × 10(8) and 3.4 × 10(8) cells in the lower and higher dose groups, respectively. No apparent adverse effects of administering bone marrow cells were observed. Compared with the lower dose, patients receiving the higher dose of bone marrow cells displayed a trend toward improved neurologic outcomes. Compared with 1 month after treatment, patients receiving cell therapy displayed a trend toward improved cerebral blood flow and metabolic rate of oxygen consumption 6 months after treatment. In comparison with historical controls, patients receiving cell therapy had significantly better neurologic outcomes. Our results indicated that intravenous transplantation of autologous bone marrow mononuclear cells is safe and feasible. Positive results and trends favoring neurologic recovery and improvement in cerebral blood flow and metabolism by cell therapy underscore the relevance of larger scale randomized controlled trials using this approach.
- Published
- 2015